Is ATH Crypto Best Buy? Analysts Target Dip After NASDAQ Linked $344M DePIN Treasury Plan Revealed On Aethir
-
最新报道：Nasdaq-listed biotech firm Predictive Oncology has committed $344 million to Aethir's ATH token, marking the first U.S. public company to hold a DePIN network token as a balance-sheet asset. The financing includes a $51.7 million cash PIPE and a $292.7 million crypto PIPE, with proceeds funding open-market ATH purchases and a 20% token grant incentive. CEO Raymond Vennare emphasized the strategic partnership for AI-driven drug discovery, while ATH's price shows bullish momentum after breaking a key downtrend, consolidating near $0.064-$0.065 with support at $0.055-$0.057.
下一篇
MicroStrategy Shareholders Face Growing Dilution Risk as Bitcoin Buys Mount
- MicroStrategy purchased 196 Bitcoin for $22.1 million at an average price of $113,048 per ...
24小时热点
热点专题
412481